In five patients with acute, severe thoracic traumatic spinal cord injuries (TSCIs), American spinal injuries association Impairment Scale (AIS) grades A-C, we induced cord hypothermia (33 °C) then rewarming (37 °C). A pressure probe and a microdialysis catheter were placed intradurally at the injury site to monitor intraspinal pressure (ISP), spinal cord perfusion pressure (SCPP), tissue metabolism and inflammation. Cord hypothermia-rewarming, applied to awake patients, did not cause discomfort or neurological deterioration. Cooling did not affect cord physiology (ISP, SCPP), but markedly altered cord metabolism (increased glucose, lactate, lactate/pyruvate ratio (LPR), glutamate; decreased glycerol) and markedly reduced cord inflammation (reduced IL1β, IL8, MCP, MIP1α, MIP1β). Compared with pre-cooling baseline, rewarming was associated with significantly worse cord physiology (increased ICP, decreased SCPP), cord metabolism (increased lactate, LPR; decreased glucose, glycerol) and cord inflammation (increased IL1β, IL8, IL4, IL10, MCP, MIP1α). The study was terminated because three patients developed delayed wound infections. At 18-months, two patients improved and three stayed the same. We conclude that, after TSCI, hypothermia is potentially beneficial by reducing cord inflammation, though after rewarming these benefits are lost due to increases in cord swelling, ischemia and inflammation. We thus urge caution when using hypothermia-rewarming therapeutically in TSCI. Hypothermia is being investigated as a potential therapy for traumatic brain injury (TBI) 1 and traumatic spinal cord injury (TSCI) 2 based on compelling evidence from several laboratories and animal species that hypothermia is neuroprotective. In animal models of TBI, hypothermia has been shown to target many pathological processes including reducing the metabolic rate, inflammation, edema, oxidative stress, excitotoxicity, electrolyte imbalance as well as apoptotic and necrotic cell death in vulnerable tissue 3-8. Despite the encouraging findings of animal studies, randomized controlled human trials have failed to show functional benefit of hypothermia in TBI patients 1,9,10. Therapeutic hypothermia is also beneficial in animal models of TSCI: rodent models of TSCI show improved histological and functional outcomes after hypothermia 11,12. Small, non-randomized studies of TSCI patients also suggest improved functional outcomes after local 13,14 or systemic hypothermia 2,15. To date, there are no published randomized controlled trials of hypothermia for TSCI. Despite the wide interest in therapeutic hypothermia for CNS injuries, there is paucity of mechanistic data from humans regarding the effect of hypothermia on the injury site. In TSCI patients, the effect of cooling and rewarming on cord swelling, metabolism and inflammation are unknown. It is thus unclear if hypothermia and